Goldstein MH, et al. – An evaluation was pursued of the safety and biological activity of isunakinra in patients with moderate to severe dry eye disease (DED). It was concluded that isunakinra was safe, well tolerated. It exhibited clinically significant improvements in signs and symptoms of DED. The yielded data encouraged the design of an adequately powered study to characterize the safety and efficacy of isunakinra in ocular surface diseases.